OrsoBio

OrsoBio is a biopharmaceutical startup that operates in the healthcare sector, specifically focusing on the development of novel treatments for severe metabolic disorders. These disorders include diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis (NASH), which is a type of liver disease caused by fat buildup in the liver. The company's approach is based on using human liver organoids, which are miniaturized and simplified versions of an organ produced in vitro in three dimensions that show realistic micro-anatomy, to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.

The company's business model revolves around the research, development, and eventual commercialization of these novel treatments. They aim to fill the significant unmet medical need for patients with severe metabolic disorders, a market with high potential due to the increasing prevalence of these conditions.

OrsoBio's team is composed of experienced physicians and scientists with decades of clinical and drug development experience from both academia and the industry. This includes their CEO, Dr. Mani Subramanian, a hepatologist with over 20 years of experience in academia and the biopharmaceutical industry, including a previous role as Vice President at Gilead Sciences.

The company generates revenue through the development and commercialization of their treatments. As a startup in the biopharmaceutical industry, they are likely also reliant on investment funding to support their research and development activities.

Keywords: Biopharmaceutical, Metabolic Disorders, Diabetes, Dyslipidemias, Lipodystrophies, Nonalcoholic Steatohepatitis (NASH), Human Liver Organoids, Drug Development, Healthcare Sector, Tailored Therapeutic Development.